Hypertension, Pulmonary
Conditions
Brief summary
The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
Detailed description
Pediatric PAH is a rare and progressive disorder associated with considerable morbidity and mortality. Given the significant medical need to develop treatments in children with PAH, further clinical studies in the pediatric population are therefore needed to provide more data for the management of PAH in children. Selexipag (JNJ-67896049) is an orally available, selective, and long-acting non-prostanoid agonist of the prostacyclin receptor approved and commercially available for the treatment of adult participants with PAH. Selexipag and its metabolite possess anti-fibrotic, anti-proliferative, and anti-thrombotic properties. Currently, no medicines targeting prostacyclin pathway are approved for pediatric use in PAH. An effective and orally available therapy acting on the prostacyclin receptor such as selexipag introduced at medically appropriate stage of PAH disease, and primarily in combination with current first-line oral PAH-specific medicines in participants in need of additional therapy because of insufficient disease control would represents a major advance to the therapeutic management of PAH pediatric participants. This study consists of a screening period of up to 6 weeks and a double-blind treatment period, including up-titration and maintenance periods, followed by a 3-year open-label extension period (OLEP) and a 30-day safety follow-up period that occurs after the last dose of study intervention (either double-blind or open-label). Safety, pharmacokinetic and efficacy assessments will be performed during the study. An Independent Data Monitoring Committee (IDMC) will be established to monitor data on an ongoing basis, to review interim data, and to ensure the continuing safety of the participants enrolled in this study. The approximate duration of the study is 8 years.
Interventions
DRUGSelexipag
Selexipag tablet will be administered orally.
DRUGPlacebo
Matching placebo tablets will be administered orally.
DRUGStandard of Care (SOC): Endothelin receptor antagonist
ERAs will be administered as SOC therapy.
DRUGSOC: Phosphodiesterase type 5 (PDE-5) inhibitor
PDE-5 inhibitor will be administered as SOC therapy.
DRUGSOC: Soluble guanylate cyclase stimulator
Soluble guanylate cyclase stimulator will be administered as SOC therapy.
Sponsors
Actelion
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
2 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Participants between greater than or equal to (\>=) 2 and less than (\<) 18 years of age weighing \>=9 kilogram (kg) at randomization * Pulmonary arterial hypertension (PAH) diagnosis confirmed by documented historical right heart catheterization (RHC) performed at any time before participant's screening * PAH (World Health Organization \[WHO\] Group 1), including participants with Down syndrome, of the following etiologies: Idiopathic PAH (IPAH); Heritable PAH (HPAH); PAH associated with congenital heart disease (PAH-associated with congenital heart disease \[aCHD\]) (PAH with coincidental CHD \[that is, a small atrial septal defect, ventricular septal defect, or patent ductus arteriosus that does not itself account for the development of elevated PVR\] and if approved by the BCAC) and Post-operative PAH (persisting / recurring/ developing \>=6 months after repair of CHD); Drug or toxin-induced; PAH associated with Human immunodeficiency virus (HIV) * WHO functional class (FC) II and III * Participants treated with at least 1 PAH-specific treatment, example, an Endothelin receptor antagonist (ERA) and/or a Phosphodiesterase type-5 (PDE-5) inhibitor/soluble guanylate cyclase stimulator, provided that the treatment dose(s) has been stable for at least 3 months prior to first dose of study intervention
Exclusion criteria
* PAH due to portal hypertension, schistosomiasis, pulmonary veno-occlusive disease, and/or pulmonary capillary hemangiomatosis * PAH associated with Eisenmenger syndrome * Previous exposure to Uptravi (selexipag) * Known concomitant life-threatening disease with a life expectancy \<12 months * Pregnant, planning to become pregnant, or lactating * Known allergies, hypersensitivity, or intolerance to selexipag or its excipients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to Disease Progression | From randomization up to 7 days after study treatment discontinuation (up to 5 years) | Time to disease progression is the time from randomization up to 7 days after study treatment discontinuation. Disease progression is defined as the first occurrence of either of the following components: Death (all causes), Atrial septostomy or Potts' anastomosis, or registration on lung transplant list, Hospitalization due to worsening pulmonary arterial hypertension (PAH), Clinical worsening of PAH. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious AEs | Up to 5 years | An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are AEs with onset during the intervention period or that are a consequence of a pre-existing condition that has worsened since baseline. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. |
| Percentage of Participants with AEs Leading to Premature Discontinuation of Study Treatment | Up to 5 years | Percentage of participants with AEs leading to premature discontinuation of study treatment will be reported. |
| Change from Baseline in Systolic and Diastolic Arterial Blood Pressure | Baseline up to end of treatment (EOT) (up to 8 years) | Change from baseline in systolic and diastolic arterial blood pressure to all assessed time points will be reported. |
| Change from Baseline in Pulse Rate | Baseline up to EOT (up to 8 years) | Change from baseline in pulse rate to all assessed time points will be reported. |
| Change from Baseline in Body Weight | Baseline up to EOT (up to 8 years) | Change from baseline in body weight to all assessed time points will be reported. |
| Change from Baseline in Height | Baseline up to EOT (up to 8 years) | Change from baseline in height to all assessed time points will be reported. |
| Sexual Maturation (Tanner Stage) Change from Baseline to all Assessed Time Points | Up to 3 days after study treatment discontinuation (up to EOT) (multiple timepoints up to 8 years) | The sexual maturation change as per Tanner stage will be assessed from baseline to all assessed time points. Tanner stage I is defined as no pubic hair at all (prepubertal Dominic state); stage II is defined as a small amount of long, downy hair with slight pigmentation at the base of the penis and scrotum (males) or on the labia majora (females); stage III is defined as when the hair becomes more coarse and curly, and begins to extend laterally; stage IV is defined as adult-like hair quality, extending across pubis but sparing medial thighs; and stage V is defined as when the: hair extends to medial surface of the thighs. |
| Percentage of Participants with Treatment-emergent Marked Laboratory Abnormalities | Baseline up to EOT (up to 8 years) | Percentage of participants with treatment-emergent marked laboratory (serum chemistry \[including pregnancy testing and thyroid markers\] and hematology) abnormalities will be reported. |
| Treatment-emergent Change from Baseline in Thyroid Stimulating Hormone | Baseline up to EOT (up to 8 years) | Treatment-emergent change from baseline in thyroid stimulating hormone over time will be reported. |
| Time to First Clinical Event Committee (CEC)-confirmed Hospitalization or Death for PAH | Until 7 days after study treatment discontinuation (Up to 8 years) | Time to first CEC-confirmed hospitalization or death for PAH is the time (days) from randomization to first occurrence of CEC-confirmed hospitalization for PAH or death due to PAH up to 7 days after study intervention discontinuation. |
| Trough Plasma Concentration at Steady-state (Ctrough,ss) of Selexipag and its Metabolite ACT-333679 | Weeks 16, 24 and every 12 weeks thereafter (up to 8 years) | Ctrough,ss is defined as the plasma concentration just prior to the morning dose, with the last study intervention administration one day prior to the pharmacokinetic sampling and will be reported for Selexipag and its metabolite ACT-333679. |
| Percentage of Participants with Treatment-emergent Electrocardiogram Abnormalities | Baseline up to EOT (up to 8 years) | Percentage of participants with treatment-emergent electrocardiogram abnormalities will be reported. |
| Change from Baseline at Week 24 in Log2 N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) | Baseline up to Week 24 | The change from baseline at week 24 in log2 NT-proBNP will be reported. |
Countries
Australia, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Lithuania, Malaysia, Mexico, Poland, Portugal, Russia, Serbia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United States, Vietnam
Contacts
STUDY_DIRECTORActelion Clinical Trial
Actelion
Outcome results
None listed